Previous Close | 0.8500 |
Open | 0.8500 |
Bid | 0.8400 x N/A |
Ask | 0.9000 x N/A |
Day's Range | 0.8500 - 0.8500 |
52 Week Range | 0.6000 - 1.3500 |
Volume | |
Avg. Volume | 12,336 |
Market Cap | 77.098M |
Beta (5Y Monthly) | 1.54 |
PE Ratio (TTM) | 4.05 |
EPS (TTM) | 0.2100 |
Earnings Date | Apr 25, 2023 - May 01, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec, today announced that it has entered into an automatic share purchase plan ("ASPP") with Raymond James Ltd. ("Raymond James"), acting as Cannara's broker, in order to facilitate repurchases of the Company's common shares ("Commo
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., announced today that further to its news release dated January 11, 2023, the Company held its annual shareholder meeting on January 25, 2023 (the "Meeting").
Cannara Biotech Inc. ("Cannara" or the "Company") (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its fiscal first quarter 2023 financial and operating results for the three-month period ended November 30, 2022.